Home » Posts tagged 'director dealing'
Tag Archives: director dealing
Cadence Minerals #KDNC – Director Share Purchase and Defined Director Purchase Programme
Cadence Minerals #KDNC announces that the Directors of the Company have acquired 6.7 million shares in the company at an average price of 0.28 pence. In addition, all of the Directors have entered into a Defined Director Purchase Programme.
Director Share Purchase
Details of the Director purchases are contained in the table below:
|
Date Purchased |
Director |
Position |
Number of ordinary shares acquired |
Price paid per share (pence) |
|
11/12/2017 |
Kiran Morzaria |
Director & CEO |
3,508,772 |
0.29 |
|
11/12/2017 |
Donald Strang |
Finance Director |
3,182,011 |
0.27 |
|
Total |
6,690,783 |
0.28 |
After these acquisitions the total notifiable share interest in the Company for the directors is as follows
|
Director |
Position |
Total Notifiable Interests (shares) |
|
Kiran Morzaria |
Director & CEO |
8,508,772 |
|
Donald Strang |
Finance Director |
3,182,011 |
|
Adrian Fairbourn |
Non-Executive Director |
6,666,667 |
|
Total |
18,357,450 |
Defined Director Purchase Programme
Andrew Suckling, Kiran Morzaria, Donald Strang and Adrian Fairbourn have all entered into a Defined Director Purchase Programme in which they will each purchase £1,000 of ordinary shares per month for 12 months. These shares will be purchased from the market on the first Friday of each month starting on 2nd February 2018 and ending the 4th January 2019. The market will be notified of the purchases on the next trading day via a PDMR; Directors dealing notification.
The Directors have entered into a DDPP in an open period and under this Programme are therefore committed to the purchase of shares in what otherwise may be a close period. Entering into the DDPP does not preclude the directors from buying additional shares in the Company during open periods.
Ends –
|
For further information, please contact. |
|
|
Cadence Minerals plc |
+44 (0) 207 440 0647 |
|
Andrew Suckling |
|
|
Kiran Morzaria |
|
|
WH Ireland Limited (NOMAD & Broker) |
+44 (0) 207 220 1666 |
|
James Joyce |
|
|
James Sinclair-Ford |
|
|
Hannam & Partners LLP (Joint Broker) |
+44 (0) 207 907 8500 |
|
Neil Passmore |
|
|
Giles Fitzpatrick |
|
|
Square1 Consulting |
+44 (0) 207 929 5599 |
|
David Bick |
About Cadence Minerals:
Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £25 million vested in key assets globally, Cadence is helping us reach tomorrow, today.
Cadence invests across the globe, principally in lithium mining projects. Its primary strategy is taking significant economic stakes in upstream exploration and development assets within strategic metals. We identify assets that have strategic cost advantages that are not replicable, with the aim of achieving lower quartile production costs. The combination of this approach and seeking value opportunities allows us to identify projects capable of achieving high rates of return.
The Cadence board has a blend of mining, commodity investing, fund management and deal structuring knowledge and experience, that is supported by access to key marketing, political and industry contacts. These resources are leveraged not only in our investment decisions but also in continuing support of our investments, whether it be increasing market awareness of an asset, or advising on product mix or path to production. Cadence Mineral’s goal is to assist management to rapidly develop the project up the value curve and deliver excellent returns on its investments.
Advanced Oncotherapy (AVO) – Additional director dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 59.75 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 773,946 Ordinary Shares representing 1.07% of the issued share capital of the Company.
|
Advanced Oncotherapy Plc |
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
Jonathan Senior / Ben Maddison |
Tel: +44 20 7710 7600 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Advanced Oncotherapy (AVO) – Additional Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 55 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 723,946 Ordinary Shares representing 1.0% of the issued share capital of the Company.
| Advanced Oncotherapy Plc | www.avoplc.com |
| Dr. Michael Sinclair, Executive Chairman | Tel: +44 20 3617 8728 |
| Nicolas Serandour, CEO | |
| Stockdale Securities (Nomad & Joint Broker) | |
| Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
| Stifel Nicolaus Europe (Joint Broker) | |
| Jonathan Senior / Ben Maddison | Tel: +44 20 7710 7600 |
| Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
| Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Tertiary Minerals (TYM) – Director Dealing, Issue of Equity, Total Voting Rights
Tertiary Minerals plc, the AIM traded company building a strategic position in the fluorspar sector announces that pursuant to terms agreed on 30 April 2014 and further to the RNS dated 20 August 2014, a non-executive director of the Company will be receiving a portion of his annual fees in ordinary shares of 1 pence each in the Company, on a six-monthly ongoing basis calculated with reference to the closing mid-market price on the trading day prior to the issue of the Ordinary Shares.
On 2 August 2016, the Company resolved to issue a total of 98,937 Ordinary Shares to Donald McAlister for the period ended 30 June 2016. The Ordinary Shares were issued at a price of 1.375 pence per share, being the closing mid-market price on 1 August 2016.
The following table shows the number of Ordinary Shares issued to Donald McAlister and his total holding following the issue of the Ordinary Shares:
|
Director |
Number of Ordinary Shares issued |
Price of Ordinary Shares issued |
Interest in total number of Ordinary Shares following Admission |
% of Company’s issued share capital following Admission |
|
Donald McAlister |
98,937 |
1.375 pence |
453,894 |
0.170% |
Application has been made to the London Stock Exchange for 98,937 Ordinary Shares to be admitted to trading on AIM (“Admission”), and it is expected that Admission will occur on or around 9 August2016.
Total Voting Rights
In accordance with Financial Conduct Authority’s Disclosure and Transparency Rules, following the issue and Admission, the total issued share capital of the Company with voting rights will be 266,944,213 ordinary shares.
The above figure of 266,944,213 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the DTRs.
Market Abuse Regulation
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail on the issue of ordinary shares to a director.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM.
1. |
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Donald McAlister |
||||
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
Non-Executive Director |
||||
|
b) |
Initial notification/Amendment: |
Initial notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Tertiary Minerals plc |
||||
|
b) |
LEI: |
213800OT9C6DQN9VO543 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary shares of 1p each |
||||
|
b) |
Nature of the transaction: |
Issue of new ordinary shares in lieu of fees |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: Aggregated volume: Price: |
Single transaction as in 4 c) above
|
||||
|
e) |
Date of the transaction: |
2016-08-02 15.00hrs UTC |
||||
|
f) |
Place of the transaction: |
Outside a trading venue |
||||
|
Enquiries
Tertiary Minerals plc Patrick Cheetham, Executive Chairman Richard Clemmey, Managing Director
|
+44 (0)1625 838 679 |
|
SP Angel Corporate Finance LLP Nominated Adviser & Joint Broker Ewan Leggat / Laura Harrison
|
+44 (0) 20 3470 0470 |
|
Beaufort Securities Ltd Joint Broker Elliot Hance
|
+44 (0)20 7382 8300 |
Notes to Editors
Tertiary Minerals plc (TYM) is an AIM-traded mineral exploration and development company building a significant strategic position in the fluorspar sector. Fluorspar is an essential raw material in the chemical, steel and aluminium industries. Tertiary controls two significant Scandinavian projects (Storuman in Sweden and Lassedalen in Norway) and a large deposit of strategic significance in Nevada USA (MB Project).
Tertiary Minerals – Director Dealing
Tertiary Minerals (TYM), the AIM traded company building a strategic position in the fluorspar sector, announces that, following Mr Richard Clemmey’s purchase of ordinary shares in the Company on 30 December 2015 as previously announced, the Company was notified on 26 January 2016 that Mr Clemmey had acquired a further 131,533 ordinary shares of 1p at a price of 1.50p per share on that date.
Following this acquisition, Mr Richard Clemmey’s total beneficial holding totals 504,037 ordinary shares representing 0.233% of the Company’s issued share capital.
Enquiries:
|
Tertiary Minerals plc Patrick Cheetham, Executive Chairman Richard Clemmey, Managing Director
|
+44 (0)845 868 4580 |
|
SP Angel Corporate Finance LLP Nominated Adviser & Joint Broker Ewan Leggat Tercel Moore
|
+44 (0)20 3470 0470 |
|
Beaufort Securities Ltd Joint Broker Jon Beliss Elliot Hance
|
+44 (0)20 7382 8300 |
|
Yellow Jersey PR Limited Dominic Barretto Aidan Stanley Brand Communications Alan Green +44 (0)7976 431608 |
Advanced Oncotherapy – Additional Director Dealing
Advanced Oncotherapy (AVO) announces that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share.
The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, on 18 December 2015 purchased 750,000 Ordinary Shares at 6.75 pence per Ordinary Share.
Following the above transactions, Michael Sinclair now holds 90,079,757 Ordinary Shares representing 6.35% of the issued share capital of the Company and Michael Bradfield now holds 124,518,510 Ordinary Shares representing 8.78% of the issued share capital of the Company.
.
|
Advanced Oncotherapy Plc |
|
|
Sanjeev Pandya, CEO |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CFO |
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Beaufort Securities (Joint Broker) |
|
|
Jon Levinson / Elliot Hance |
Tel: +44 20 7382 8300 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy Brand Communications Alan Green |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 Tel: +44 1273 704473 Mob: +44 7976 431608 |
Advanced Oncotherapy – Additional Director Dealing
Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 1,000,000 ordinary shares of 1 penny each in the Company at 5.75 pence per Ordinary Share.
Following this transaction, Michael Bradfield now holds 123,768,510 Ordinary Shares representing 8.73% of the issued share capital of the Company.
|
Advanced Oncotherapy Plc |
|
|
Sanjeev Pandya, CEO |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CFO |
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Beaufort Securities (Joint Broker) |
|
|
Jon Levinson / Elliot Hance |
Tel: +44 20 7382 8300 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy Brand Communications Alan Green |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 Tel: +44 1273 704473 Mob: +44 7976 431608 |
Advanced Oncotherapy – Director Dealing
Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 750,000 ordinary shares of 1 penny each in the Company at 5.5 pence per Ordinary Share.
Following this transaction, Michael Bradfield now holds 122,768,510 Ordinary Shares representing 8.66% of the issued share capital of the Company.
|
Advanced Oncotherapy Plc |
|
|
Sanjeev Pandya, CEO |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CFO |
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Beaufort Securities (Joint Broker) |
|
|
Jon Levinson / Elliot Hance |
Tel: +44 20 7382 8300 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy
Brand Communications Alan Green |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001
Tel: +44 1273 704473 Mob: +44 7976 431608 |